Discovery of an autoantibody signature for the early diagnosis of knee osteoarthritis: Data from the Osteoarthritis Initiative

María Camacho-Encina, Vanesa Balboa-Barreiro, Ignacio Rego-Perez, Florencia Picchi, Jennifer Vanduin, Ji Qiu, Manuel Fuentes, Natividad Oreiro, Joshua LaBaer, Cristina Ruiz-Romero, Francisco J. Blanco

Research output: Contribution to journalArticle

Abstract

Objective: To find autoantibodies (AAbs) in serum that could be useful to predict incidence of radiographic knee osteoarthritis (KOA). Design: A Nucleic-acid Programmable Protein Arrays (NAPPA) platform was used to screen AAbs against 2125 human proteins in sera at baseline from participants free of radiographic KOA belonging to the incidence and non-exposed subcohorts of the Osteoarthritis Initiative (OAI) who developed or not, radiographic KOA during a follow-up period of 96 months. NAPPA-ELISA were performed to analyse reactivity against methionine adenosyltransferase two beta (MAT2β) and verify the results in 327 participants from the same subcohorts. The association of MAT2β-AAb levels with KOA incidence was assessed by combining several robust biostatistics analysis (logistic regression, Receiver Operating Characteristic and Kaplan-Meier curves). The proposed prognostic model was replicated in samples from the progression subcohort of the OAI. Results: In the screening phase, six AAbs were found significantly different at baseline in samples from incident compared with non-incident participants. In the verification phase, high levels of MAT2β-AAb were significantly associated with the future incidence of KOA and with an earlier development of the disease. The incorporation of this AAb in a clinical model for the prognosis of incident radiographic KOA significantly improved the identification/classification of patients who will develop the disorder. The usefulness of the model to predict radiographic KOA was confirmed on a different OAI subcohort. Conclusions: The measurement of AAbs against MAT2β in serum might be highly useful to improve the prediction of OA development, and also to estimate the time to incidence.

Original languageEnglish (US)
JournalAnnals of the Rheumatic Diseases
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Knee Osteoarthritis
Osteoarthritis
Autoantibodies
Early Diagnosis
Nucleic Acids
Incidence
Methionine Adenosyltransferase
Protein Array Analysis
Proteins
Logistics
Biostatistics
Screening
Serum
ROC Curve
Blood Proteins
Logistic Models
Enzyme-Linked Immunosorbent Assay

Keywords

  • autoantibodies
  • biomarkers
  • diagnosis
  • osteoarthritis
  • prognosis

ASJC Scopus subject areas

  • Rheumatology
  • Immunology and Allergy
  • Immunology
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Discovery of an autoantibody signature for the early diagnosis of knee osteoarthritis : Data from the Osteoarthritis Initiative. / Camacho-Encina, María; Balboa-Barreiro, Vanesa; Rego-Perez, Ignacio; Picchi, Florencia; Vanduin, Jennifer; Qiu, Ji; Fuentes, Manuel; Oreiro, Natividad; LaBaer, Joshua; Ruiz-Romero, Cristina; Blanco, Francisco J.

In: Annals of the Rheumatic Diseases, 01.01.2019.

Research output: Contribution to journalArticle

Camacho-Encina, María ; Balboa-Barreiro, Vanesa ; Rego-Perez, Ignacio ; Picchi, Florencia ; Vanduin, Jennifer ; Qiu, Ji ; Fuentes, Manuel ; Oreiro, Natividad ; LaBaer, Joshua ; Ruiz-Romero, Cristina ; Blanco, Francisco J. / Discovery of an autoantibody signature for the early diagnosis of knee osteoarthritis : Data from the Osteoarthritis Initiative. In: Annals of the Rheumatic Diseases. 2019.
@article{c5009be0b4e64f9b9a690b0428e68381,
title = "Discovery of an autoantibody signature for the early diagnosis of knee osteoarthritis: Data from the Osteoarthritis Initiative",
abstract = "Objective: To find autoantibodies (AAbs) in serum that could be useful to predict incidence of radiographic knee osteoarthritis (KOA). Design: A Nucleic-acid Programmable Protein Arrays (NAPPA) platform was used to screen AAbs against 2125 human proteins in sera at baseline from participants free of radiographic KOA belonging to the incidence and non-exposed subcohorts of the Osteoarthritis Initiative (OAI) who developed or not, radiographic KOA during a follow-up period of 96 months. NAPPA-ELISA were performed to analyse reactivity against methionine adenosyltransferase two beta (MAT2β) and verify the results in 327 participants from the same subcohorts. The association of MAT2β-AAb levels with KOA incidence was assessed by combining several robust biostatistics analysis (logistic regression, Receiver Operating Characteristic and Kaplan-Meier curves). The proposed prognostic model was replicated in samples from the progression subcohort of the OAI. Results: In the screening phase, six AAbs were found significantly different at baseline in samples from incident compared with non-incident participants. In the verification phase, high levels of MAT2β-AAb were significantly associated with the future incidence of KOA and with an earlier development of the disease. The incorporation of this AAb in a clinical model for the prognosis of incident radiographic KOA significantly improved the identification/classification of patients who will develop the disorder. The usefulness of the model to predict radiographic KOA was confirmed on a different OAI subcohort. Conclusions: The measurement of AAbs against MAT2β in serum might be highly useful to improve the prediction of OA development, and also to estimate the time to incidence.",
keywords = "autoantibodies, biomarkers, diagnosis, osteoarthritis, prognosis",
author = "Mar{\'i}a Camacho-Encina and Vanesa Balboa-Barreiro and Ignacio Rego-Perez and Florencia Picchi and Jennifer Vanduin and Ji Qiu and Manuel Fuentes and Natividad Oreiro and Joshua LaBaer and Cristina Ruiz-Romero and Blanco, {Francisco J.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1136/annrheumdis-2019-215325",
language = "English (US)",
journal = "Annals of the Rheumatic Diseases",
issn = "0003-4967",
publisher = "BMJ Publishing Group",

}

TY - JOUR

T1 - Discovery of an autoantibody signature for the early diagnosis of knee osteoarthritis

T2 - Data from the Osteoarthritis Initiative

AU - Camacho-Encina, María

AU - Balboa-Barreiro, Vanesa

AU - Rego-Perez, Ignacio

AU - Picchi, Florencia

AU - Vanduin, Jennifer

AU - Qiu, Ji

AU - Fuentes, Manuel

AU - Oreiro, Natividad

AU - LaBaer, Joshua

AU - Ruiz-Romero, Cristina

AU - Blanco, Francisco J.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Objective: To find autoantibodies (AAbs) in serum that could be useful to predict incidence of radiographic knee osteoarthritis (KOA). Design: A Nucleic-acid Programmable Protein Arrays (NAPPA) platform was used to screen AAbs against 2125 human proteins in sera at baseline from participants free of radiographic KOA belonging to the incidence and non-exposed subcohorts of the Osteoarthritis Initiative (OAI) who developed or not, radiographic KOA during a follow-up period of 96 months. NAPPA-ELISA were performed to analyse reactivity against methionine adenosyltransferase two beta (MAT2β) and verify the results in 327 participants from the same subcohorts. The association of MAT2β-AAb levels with KOA incidence was assessed by combining several robust biostatistics analysis (logistic regression, Receiver Operating Characteristic and Kaplan-Meier curves). The proposed prognostic model was replicated in samples from the progression subcohort of the OAI. Results: In the screening phase, six AAbs were found significantly different at baseline in samples from incident compared with non-incident participants. In the verification phase, high levels of MAT2β-AAb were significantly associated with the future incidence of KOA and with an earlier development of the disease. The incorporation of this AAb in a clinical model for the prognosis of incident radiographic KOA significantly improved the identification/classification of patients who will develop the disorder. The usefulness of the model to predict radiographic KOA was confirmed on a different OAI subcohort. Conclusions: The measurement of AAbs against MAT2β in serum might be highly useful to improve the prediction of OA development, and also to estimate the time to incidence.

AB - Objective: To find autoantibodies (AAbs) in serum that could be useful to predict incidence of radiographic knee osteoarthritis (KOA). Design: A Nucleic-acid Programmable Protein Arrays (NAPPA) platform was used to screen AAbs against 2125 human proteins in sera at baseline from participants free of radiographic KOA belonging to the incidence and non-exposed subcohorts of the Osteoarthritis Initiative (OAI) who developed or not, radiographic KOA during a follow-up period of 96 months. NAPPA-ELISA were performed to analyse reactivity against methionine adenosyltransferase two beta (MAT2β) and verify the results in 327 participants from the same subcohorts. The association of MAT2β-AAb levels with KOA incidence was assessed by combining several robust biostatistics analysis (logistic regression, Receiver Operating Characteristic and Kaplan-Meier curves). The proposed prognostic model was replicated in samples from the progression subcohort of the OAI. Results: In the screening phase, six AAbs were found significantly different at baseline in samples from incident compared with non-incident participants. In the verification phase, high levels of MAT2β-AAb were significantly associated with the future incidence of KOA and with an earlier development of the disease. The incorporation of this AAb in a clinical model for the prognosis of incident radiographic KOA significantly improved the identification/classification of patients who will develop the disorder. The usefulness of the model to predict radiographic KOA was confirmed on a different OAI subcohort. Conclusions: The measurement of AAbs against MAT2β in serum might be highly useful to improve the prediction of OA development, and also to estimate the time to incidence.

KW - autoantibodies

KW - biomarkers

KW - diagnosis

KW - osteoarthritis

KW - prognosis

UR - http://www.scopus.com/inward/record.url?scp=85071762726&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85071762726&partnerID=8YFLogxK

U2 - 10.1136/annrheumdis-2019-215325

DO - 10.1136/annrheumdis-2019-215325

M3 - Article

C2 - 31471297

AN - SCOPUS:85071762726

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

SN - 0003-4967

ER -